Skip to content

A Cohort Study for Clinical Evaluation of OmniMax MMF System

The OmniMax MMF System: A Cohort Study for Clinical Evaluation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03075865
Acronym
OmniMax
Enrollment
39
Registered
2017-03-09
Start date
2017-06-28
Completion date
2019-06-28
Last updated
2021-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mandibular Fractures

Keywords

intermaxillary fixation, maxillo-mandibular fixation

Brief summary

OmniMax MMF system was designed as a device with faster application/removal time, less mucosal tissue overgrowth over the plates and screws, better tolerance for placement over prolong periods of time, better patient hygiene and a lower risk for further treatments secondary to root damage from the insertion of the screws, compared to the standard of care for maxillo-mandibular fixation and other hybrid systems. This clinical trial intends to highlight the clinical benefits of the OmniMax MMF system applied to patients undergoing repair of uncomplicated mandibular fracture(s) for whom OmniMax MMF system is used as a single mean for maxillo-mandibular fixation.

Detailed description

The objective of this study is to highlight and evaluate the clinical benefits of OmniMax MMF system applied to patients undergoing repair of uncomplicated mandibular fracture(s). A total of 50 subjects involved in trauma events resulting in uncomplicated mandibular fracture(s) will be enrolled at up to 5 sites from 3 surgical subspecialties: maxillofacial surgery, ENT, and plastic surgery. Subjects considered for participation will receive OmniMax MMF system for maxillo-mandibular fixation for a period of 4 to 8 weeks. Incidence of root damage associated with screw insertion, time for implantation and removal of the device, oral hygiene during the maxillomandibular fixation period, mucosal overgrowth, gingival necrosis, post-operative pain, stability of the occlusion, fracture healing, patient overall satisfaction/compliance with length of treatment, incidence of glove perforation and accidental puncture, will be evaluated in all participants who remain in IMF post-operatively. Adverse Events associated with the use of OmniMax MMF system will also be collected.

Interventions

DEVICEOmniMax MMF system

OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.

Sponsors

University of Iowa
CollaboratorOTHER
Medical University of South Carolina
CollaboratorOTHER
University of California, Davis
CollaboratorOTHER
Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males or females * 18 years of age or older * Able and willing to sign ICF and medical photography consent * Undergoing a surgical procedure to repair uncomplicated mandibular fracture(s) requiring open reduction internal fixation (ORIF) or closed maxillo-mandibular fixation (MMF) * Fracture repair done within 10 days after facial trauma * Use of OmniMax MMF system as a single mean for IMF (maxillary plate and mandibular plates together with no other device combined, such as Erich bars or IMF screws).

Exclusion criteria

* General contraindications unfavorable for the use of MMF (psychological disorders, seizures disorders, airway compromise, immune-compromised patients, etc). * History of radiation therapy to the head or neck region. * Limited blood supply to the area of device application. * Insufficient quantity or quality of bone. * History of foreign body sensitivity. * History of previous use of bisphosphonates (i.e. alendronate, pamidronate, neridronate, olpadronate, ibandronate, risendronate, zolendronate). * Clinically active or latent infection. * Patients with less than 20 teeth. * Deciduous dentition. * Patients for whom the use of OmniMax MMF system would not be appropriate in judgment of the surgeon (i.e., excessive overjet or deep overbite). * Mandibular fracture pattern that could prevent the use of OmniMax MMF system for adequate reduction and stabilization (i.e., comminuted fractures, dental alveolar fractures).

Design outcomes

Primary

MeasureTime frameDescription
Root Damage6 weeksDental root damage can be caused from insertion of the screws at time of implantation. Some of these events may require further medical or surgical treatment

Secondary

MeasureTime frameDescription
Time for Implantation of OmniMax MMFOperativeThe OmniMax MMF system, with a better segmentalized design and extended screw slots, allows for fixation of this device using less quantity of screws for fixation (compared to other hybrid systems). This system may impact the efficiency of the medical care by significantly reducing the operative time.
Tissue necrosis and mucosal overgrowth6 weeksThe reduced number of screws needed to fixate a full OmniMax MMF system (8 versus up to 14 in other bone-borne systems) is expected to improve the post-operative gingival tissue health, avoiding soft tissue irritation, overgrowth, compression and necrosis of the gingival area.

Other

MeasureTime frameDescription
Gloves Perforation and Accidental PunctureOperativeDesign of OmniMax MMF system is expected to reduce the risk for accidental glove perforation and/or wire puncture during implantation of the device.
Patient Satisfaction6 weeksLess screws for fixation and design of the device to protect the soft tissue is expected to increase the level of patient satisfaction and patient compliance with both, the oral hygiene and the length of fixation period.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026